Is Juvelook FDA-Approved? A MoCRA Serum and MFDS Mark Are Not a Filler PMA

As South Korean aesthetic innovations continue to capture global attention, Juvelook and its higher-density sibling Juvelook Volume (marketed internationally as Lenisna) have emerged among the most frequently requested "skin booster" and biostimulatory injectable treatments. Formulated as a hybrid combining micro-spherical poly-D,L-lactic acid (PDLLA) with non-crosslinked hyaluronic acid (HA), Juvelook is heavily promoted across social media, medical-tourism portals in Seoul, and aesthetic clinics across Europe and Asia for skin texture improvement, fine lines, acne scarring, and subtle volume restoration.

However, prospective American patients searching for the treatment frequently encounter contradictory and misleading claims. Several prominent international and domestic medical spa websites advertise Juvelook as "FDA-approved." One ranking clinic in Seoul even claims that Juvelook Volume has "received FDA approval specifically for the treatment of undereye hollows." Meanwhile, boutique clinics in Beverly Hills and Los Angeles advertise Juvelook injectable sessions, while the manufacturer's official U.S. subsidiary in Irvine, California, lists a skincare serum bearing an FDA cosmetic MoCRA registration with the explicit warning: not intended for injection.

The regulatory reality is unambiguous: No. Juvelook is not an FDA-approved dermal filler or skin booster in the United States.

Juvelook holds zero Premarket Approvals (PMA) from the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH). It has never received a Class III medical device approval order under Product Code LMH, it has no public Summary of Safety and Effectiveness Data (SSED), and poly-D,L-lactic acid is completely absent from the official FDA registry of approved dermal filler materials. While Juvelook possesses medical-device approval from South Korea's Ministry of Food and Drug Safety (MFDS) and a European CE mark, those foreign clearances grant zero legal authority to market or administer the product as an injectable medical device in the United States.

This reference guide provides an exhaustive regulatory and clinical audit of Juvelook. We examine the federal PMA database census, unpack why a cosmetic registration under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) does not authorize an injectable, dissect the false "undereye FDA approval" claims circulating on search engine result pages, expose common polymer mix-ups with Ellansé and Sculptra, compare Juvelook to legitimate FDA-approved alternatives like Skinvive and Sculptra, and outline exactly what patients must ask before accepting a quote.

---

Direct Summary: Juvelook U.S. Regulatory Status at a Glance

---

Is Juvelook FDA-approved as a US dermal filler, or only MFDS- and CE-marked abroad?

To evaluate why clinic claims of "FDA approval" are legally baseless, prospective patients must understand the stringent regulatory mechanism governing aesthetic injectables in the United States.

U.S. Class III Device PMA vs. Foreign Authorization Landscape:
┌───────────────────────────────────────────────┬───────────────────────────────────────────────┐
│ U.S. FDA Premarket Approval (PMA / CDRH)      │ Foreign Approvals (MFDS / CE Mark / TGA)      │
├───────────────────────────────────────────────┼───────────────────────────────────────────────┤
│ • Regulated under FD&C Act § 515 (21 CFR 814) │ • Korean Medical Device Act (MFDS / KFDA)     │
│ • Classification: Class III Medical Device    │ • European Union Medical Device Reg (MDR)     │
│ • Valid scientific evidence of safety and     │ • Conformance assessed by a Notified Body    │
│   effectiveness; typically includes clinical  │   (CE)                                       │
│   data and a public SSED plus Approval Order  │ • Manufacturer states CE / MFDS / TGA marks  │
│ • Product Code LMH (Dermal Implant)           │ • Valid ONLY within issuing jurisdictions     │
│ • Premarket approval mandatory before sale    │ • Conveys ZERO legal authority in the U.S.   │
└───────────────────────────────────────────────┴───────────────────────────────────────────────┘

The Federal Regulatory Threshold for Injectable Implants

In the United States, injectable materials intended to augment soft tissue, correct facial wrinkles, or improve skin smoothness are classified by federal statute as Class III medical devices. Because these biomaterials are placed beneath the skin and remain implanted in human tissue for months or years, the Federal Food, Drug, and Cosmetic Act (FD&C Act) classifies them in the highest risk category.

Under 21 U.S.C. § 360e, a Class III medical device cannot be legally introduced into interstate commerce for human clinical use without an approved Premarket Approval (PMA) application. A PMA is the most rigorous device application the FDA uses. The manufacturer must provide valid scientific evidence of a reasonable assurance of safety and effectiveness for specified indications. That evidence often includes clinical trials, but the statute does not reduce to a single mandatory US multicenter RCT template that can be assumed for every Class III implant.

When the FDA approves a PMA, CDRH publishes a formal Approval Order and a Summary of Safety and Effectiveness Data (SSED). Those documents are the public record of what was studied — sample size, endpoints, and adverse events for a specific finished device and indication. They are not transferable to a different polymer, manufacturer, or foreign SKU.

The FDA Premarket Approval Database Census

An independent recount of the FDA CDRH Premarket Approval database used for this page—snapshot date 24 August 2026, 56,765 rows, latest decision date 10 July 2026—confirms that Juvelook has never received premarket approval:

FDA Premarket Approval (PMA) Database Census
Snapshot: 24 August 2026 (latest decision date 10 July 2026)
Total records: 56,765
Product code LMH (dermal implant): 1,046
Product code PKY (hand dermal implant): 2
Trade name / generic name / applicant strings Juvelook, Lenisna, VAIM, VAIM Global, VAIM USA, Juvetek: 0

P030050 family (Sculptra PLLA, applicant of record Q-Med AB): 54 rows
  Original order 3 August 2004; S039 cheek wrinkles 25 April 2023
LMH rows whose trade or generic name contains "lactic": 15
  All 15 are P030050; none are PDLLA or Juvelook

Across all 1,046 LMH records—the product code the FDA fillers page tells readers to search—there are zero rows for Juvelook, Lenisna, or VAIM. The only lactic-acid filler family in that snapshot is Sculptra (PMA P030050), which is poly-L-lactic acid (PLLA), not PDLLA.

Similarly, an audit of the FDA 510(k) Premarket Notification database used here (snapshot date 24 August 2026, 175,559 rows) finds zero device-name or applicant rows for Juvelook, Lenisna, VAIM, or Juvetek, and zero device-name hits for PDLLA as an aesthetic injectable. Lactide-related 510(k)s in that snapshot are bioresorbable orthopedic fixation (including Biofix poly-L-lactide screws) and surgical sutures (including PGLA), not dermal implants.

The Official FDA-Approved Dermal Fillers Register

The FDA CDRH maintains a dedicated public reference page titled FDA-Approved Dermal Fillers (last updated 9 November 2020). The FDA categorizes all lawful dermal filler materials into four discrete chemical classes:

1. Hyaluronic Acid (HA): A naturally occurring glycosaminoglycan, crosslinked with agents like BDDE to provide temporary structural volumization degradable by hyaluronidase (e.g., Juvéderm, Restylane, Belotero, RHA).
2. Calcium Hydroxylapatite (CaHA): Synthetic mineral microparticles suspended in a carboxymethylcellulose aqueous gel (Radiesse, PMA P050037 / P050052, analyzed in our review of Radiesse longevity).
3. Poly-L-lactic Acid (PLLA): A biodegradable synthetic polymer that triggers host neocollagenesis over several months (Sculptra, PMA P030050).
4. Polymethylmethacrylate (PMMA): Non-resorbable synthetic microspheres in bovine collagen (Bellafill, PMA P020012, detailed in our guide to permanent PMMA filler).

Poly-D,L-lactic acid (PDLLA) is completely absent from the FDA register. The presence of PLLA on this list does not extend to PDLLA. In polymer chemistry and regulatory law, stereo-isomeric polymers possess different crystallinity, degradation rates, and biological interactions; an approval for one polymer formulation cannot be transferred to a distinct stereoisomer.

Foreign Certifications: MFDS, CE Mark, and TGA

Juvelook's actual regulatory standing is rooted abroad, as stated by the manufacturer rather than by an independently retrieved Korean or Australian certificate number:

• South Korea (MFDS): The manufacturer FAQ retrieved 8 September 2026 says Juvelook and Juvelook Volume (Lenisna) have received medical-device approval from Korea's Ministry of Food and Drug Safety (MFDS; formerly KFDA).
• European Union (CE Mark): The same FAQ states they are CE-marked Class III medical devices. Approved indications, product names, and availability may vary by country.
• Australia (TGA): The benefits page lists medical-device registrations as CE, KFDA, and TGA. This page does not reprint an ARTG number or independently verified Australian indication.

Those foreign marks carry zero statutory authority in the United States. The FDA does not grant automatic reciprocity for Class III implantable medical devices. Without a U.S. PMA, marketing or administering injectable Juvelook in the United States is commercial use of an unapproved medical device under the FD&C Act—not off-label use of an approved filler.

---

Does a VAIM USA MoCRA serum, PDLLA polymer history, or Sculptra PLLA approval make injectable Juvelook a PMA?

In marketing brochures and online consultations, clinics that promote Juvelook frequently deploy three sophisticated arguments to convince prospective patients that the product is effectively "cleared" or "recognized" by the FDA. Each of these arguments collapses under legal and scientific scrutiny.

Deconstructing the Three False-Equivalence Arguments:
┌───────────────────────────────┬───────────────────────────────┬───────────────────────────────┐
│ 1. The MoCRA Cosmetic Trap    │ 2. The Polymer Fallacy        │ 3. The Stereoisomer Conflation│
├───────────────────────────────┼───────────────────────────────┼───────────────────────────────┤
│ "VAIM USA has an FDA number"  │ "PDLLA is biodegradable"      │ "It is just like Sculptra"    │
│                               │                               │                               │
│ • VAIM USA lists MoCRA        │ • Biodegradability or suture  │ • Sculptra uses PLLA          │
│   #53-670426-700897.          │   history does NOT equal a    │   (semi-crystalline).         │
│ • Governed by MoCRA 2022      │   Class III medical device    │ • Juvelook uses PDLLA         │
│   cosmetic facility rules.    │   Premarket Approval (PMA).   │   (amorphous racemic mix).    │
│ • Explicitly labeled:         │ • Requires proof of safety    │ • S039 PMA approval does not  │
│   "For topical use only;      │   and clinical efficacy in    │   grant regulatory clearance  │
│   Not intended for injection."│   specific human tissues.     │   to a different polymer.     │
└───────────────────────────────┴───────────────────────────────┴───────────────────────────────┘

1. The MoCRA Cosmetic Serum Conflation

The most significant recent source of confusion is the commercial presence of VAIM USA, operating out of Irvine, California.

On its commercial portal (usa.juvelook.com), VAIM USA markets JUVELOOK Professional Skincare. Marketing materials and online distributor listings proudly display an FDA registration code: FDA MoCRA #53-670426-700897. Unwary patients and non-physician injectors frequently point to this registration number as proof that "Juvelook has FDA clearance."

This is a complete misunderstanding of federal law:

• The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) created mandatory facility registration and product listing requirements for cosmetic manufacturers distributing skincare products in the United States (examined in our analysis of MoCRA cosmetic deadlines).
• A MoCRA listing is not an FDA approval. The FDA does not review cosmetic safety data, does not inspect clinical trial results, and does not "approve" cosmetic formulations.
• Crucially, VAIM USA’s own product labeling explicitly defines its legal boundary: "For professional topical use; Not intended for injection."

JUVELOOK Professional Skincare is formulated as a topical, post-procedure serum intended to be applied onto the surface of the skin following superficial treatments like microneedling or non-ablative laser resurfacing. Transforming a topically registered cosmetic serum into an injectable by loading it into a syringe and puncturing the dermis violates federal labeling, bypasses Class III device controls, and exposes patients to significant microbiological and foreign-body risks. A MoCRA cosmetic number provides zero regulatory cover for an injectable treatment.

For a deeper dive into how cosmetic establishment registrations differ from medical device clearances, see our clinician guide to FDA-cleared vs. FDA-registered aesthetic products.

2. The "Biodegradable Polymer" Fallacy

A second common argument—exemplified by clinic FAQs such as that of Edition Clinic Bangkok—asserts that Juvelook is "FDA approved because its components (PDLLA and hyaluronic acid) are biodegradable substances recognized by the FDA."

This line of reasoning commits a fundamental category error:

• Materials vs. Finished Devices: The FDA does not approve abstract chemical substances in isolation; it approves specific finished medical devices manufactured under strict specifications for precise indications for use.
• Suture History vs. Dermal Implantation: Polylactic acid derivatives have long been used in FDA-cleared resorbable sutures and orthopedic screws. That 510(k) history is a different product class. Injecting microparticles into facial soft tissue is a Class III dermal-implant question, which is why the FDA fillers page points readers to product codes LMH and PKY rather than to suture clearances.
• In soft tissue, microparticles interact directly with dermal dendritic cells and tissue macrophages, triggering chronic foreign-body cascades. The fact that a polymer eventually breaks down into water and carbon dioxide via the Krebs cycle does not eliminate the risks of granuloma formation, sterile abscesses, or delayed nodules. Premarket Approval requires clinical proof that the specific particle size, sphericity, porosity, and degradation kinetics perform safely in human facial tissue.

3. PLLA (Sculptra) vs. PDLLA (Juvelook): The Stereoisomer Distinction

The third misconception conflates Juvelook with Sculptra. Because Sculptra is an FDA-approved biostimulator (PMA P030050), some injectors suggest that Juvelook is simply "the next generation of Sculptra" and therefore shares its regulatory validation.

Chemically and biologically, the two products are fundamentally different:

While PDLLA's spherical, porous architecture is the manufacturer's design story, that story does not bypass federal law. Peer-reviewed PDLLA papers exist; they are not a PMA. Seo et al. (J Cosmet Dermatol 2024;23:794–802, PMID 37969055, DOI 10.1111/jocd.16085) is a preliminary human rejuvenation study of combined PDLLA and non-crosslinked HA, funded by VAIM Co., Ltd. Lee et al. (Polymers 2024;16(18):2583, PMID 39339047, PMC11434839) is a dermatology literature review, not an FDA SSED. Sculptra's clinical dossier cannot be borrowed by Juvelook.

---

Why do ranking clinics say US FDA-approved, including an undereye indication?

A search on Google for "is juvelook fda approved" returns a troubling volume of misinformation across medical spa blogs, international clinics, and social media platforms. Auditing these specific claims reveals how commercial marketing distorts regulatory reality.

1. The Jeunex Clinic "Undereye FDA Approval" Fabrication

The most egregious example appears on the website of Jeunex Clinic (a medical aesthetic clinic in Seoul ranking at position 2 organically for the query). On its page dedicated to Juvelook Volume for dark undereye circles, the clinic's FAQ explicitly asserts:

"Yes, Juvelook Volume has received FDA approval specifically for the treatment of undereye hollows and associated dark circles. It's important to note that this specialized approval makes it different from general dermal fillers that may be used 'off-label' in the tear trough area."

That FAQ answer is false as a US regulatory statement:

1. Juvelook Volume has never received FDA approval for any indication. The 24 August 2026 PMA snapshot has zero matching product-name or applicant rows.
2. The infraorbital hollow is a high-risk zone: thin skin, lymphatic congestion, and named vessels including the angular and infraorbital arteries. Vascular occlusion is a named filler risk on the FDA dermal-fillers page.
3. US on-label infraorbital hyaluronic acid fillers are not "two products in history." They are Juvéderm Volbella XC (P110033/S053, 28 May 2021), Restylane Eyelight (P040024/S135, 8 May 2023), Belotero Balance (+) (P090016/S050, 27 September 2023), and RHA Redensity Eye (P170002/S050, 12 May 2026). Do not confuse S048 — that 18 September 2025 supplement is RHA 4 / Dynamic Volume, not the under-eye SKU. Details on the actual under-eye PMA live in RHA Redensity under-eye FDA approval.
4. Particulate biostimulators are a poor fit for the tear trough because delayed, non-dissolvable nodules can show through thin eyelid skin. A 2025 Journal of Cosmetic Dermatology case report describes nodular reaction after PDLLA injection for tear-trough rejuvenation (PMID 39283001). That paper is literature about a complication, not a PMA, and this page does not reprint its energy-device management steps.

2. The Girin and Edition Clinic Broad Claims

Other international clinic websites display similar misrepresentations:

• Girin Plastic Surgery (Seoul) writes that Juvelook has received "approval from both the U.S. FDA and the Korean FDA."
• Edition Clinic (Bangkok, updated April 2026) states that Juvelook has "regulatory approvals from the KFDA (Korean FDA), Thai FDA, US FDA, and CE Mark certification in Europe," and separately that PDLLA and hyaluronic acid "are biodegradable." Biodegradable ingredients plus a foreign mark are not a US filler PMA.
• Numerous aesthetic medical spa accounts on Instagram and Facebook across North America and the Philippines routinely publish promotional reels labeling Juvelook as "Korean and US FDA-approved."

In many cases, clinic copywriters confuse the FDA establishment registration of an overseas export manufacturer, or the MoCRA cosmetic listing of VAIM USA's topical skincare line, with an official device approval. In other instances, it represents deliberate marketing hyperbole designed to reassure hesitant international travelers and medical tourists.

3. Domestic Mix-Ups: The Halo Beverly Hills "PCL" Conflation

Misinformation is not confined to overseas providers. In Southern California, aesthetic clinics openly rank for search queries like "can you get juvelook in the us".

On the service pages of Halo Beverly Hills, Juvelook and Juvelook Volume are listed under injectable procedures. While the clinic’s Juvelook Volume page correctly references PDLLA, its primary Juvelook service page describes the product as consisting of polycaprolactone (PCL) microspheres.

This is a blatant chemical and product mix-up:

• Polycaprolactone (PCL) is the active polymer in Ellansé, an injectable manufactured by Sinclair Pharma that is popular in Europe and Asia (analyzed in our investigation of Ellansé FDA status).
• Juvelook contains zero polycaprolactone. It is composed strictly of poly-D,L-lactic acid and hyaluronic acid.
• When prominent aesthetic practices confuse the fundamental chemical polymer of the product they are marketing, patients must exercise extreme caution regarding provider knowledge and product provenance.

---

Can you get injectable Juvelook in the United States, and is that the same product as the Irvine topical?

The intersection of patient demand and regulatory restriction has created a fragmented, two-tier market for Juvelook within the United States.

Juvelook in the U.S. Market: Authorized Topical vs. Clinic Injectable Copy:
┌───────────────────────────────────────────────┬───────────────────────────────────────────────┐
│ VAIM USA Authorized SKU (Irvine, CA)          │ What ranking US clinic pages describe         │
├───────────────────────────────────────────────┼───────────────────────────────────────────────┤
│ • Product: JUVELOOK Professional Skincare     │ • Halo BH and Cara LA describe injection     │
│ • Classification: Topical Cosmetic Serum      │ • Halo non-Volume page calls the polymer PCL │
│ • Regulatory ID: FDA MoCRA #53-670426-700897  │ • Regulatory ID: Zero U.S. PMA / 510(k)      │
│ • Labeled: professional topical use;          │ • This census cannot prove vial provenance   │
│   "NOT INTENDED FOR INJECTION"                │ • Not off-label use of an LMH PMA            │
└───────────────────────────────────────────────┴───────────────────────────────────────────────┘

1. The Legitimate U.S. SKU: Professional Topical Serum

If a U.S. medical spa purchases Juvelook through official domestic commercial channels via VAIM USA, they receive a topical skincare serum.

This product is manufactured under cosmetic standards. It is intended to be applied topically over the skin barrier, often following energy-based treatments or mechanical microneedling (such as SkinPen), to provide superficial hydration and cosmetic conditioning.

However, because patient demand is centered on the dramatic skin-firming results seen in Korean clinical photos, some providers face commercial temptation. Applying a cosmetic serum topically produces subtle, superficial results; injecting it into the dermis delivers the particulate payload directly to tissue fibroblasts. Yet doing so directly violates the manufacturer’s instructions (not intended for injection), voids product liability protections, and exposes the patient to serious adverse risks from unsterilized or cosmetically preserved ingredients.

2. What US clinic pages actually show

How, then, do pages in Los Angeles and Beverly Hills offer Juvelook as an injectable?

They describe injection. Halo Beverly Hills files JuveLook under injectables and misstates the polymer as PCL. Cara Plastic Surgery calls it a hybrid biostimulatory injectable. This page does not claim to know how any named clinic currently sources vials, whether the SKU on the tray is the Irvine topical, or whether a specific import path was used. Those are questions for the consultation, not facts this census can prove.

What the public record does show:

• VAIM USA's listed US product is a topical serum, labeled not for injection, with a MoCRA number.
• Injectable Juvelook has zero US PMA or 510(k) as a dermal filler in the snapshots used here.
• Off-label use applies only to a product that already holds FDA approval. Injecting a product with no approval is not off-label Sculptra or Skinvive use; it is use of an unapproved device (see off-label aesthetic injections).

Unapproved imported injectables, as a class, also lack a US chain of custody. Temperature history, sterility of the vial, and authenticity cannot be verified from a spa menu. That is a class risk of gray-market devices, not a claim that a named clinic is currently injecting a counterfeit Juvelook lot.

---

How does Juvelook differ from Sculptra, Skinvive, Rejuran, and Ellansé?

Patients considering Juvelook are almost always evaluating it against other high-profile skin-rejuvenation and biostimulatory treatments. Understanding the clinical, regulatory, and mechanical differences is essential for choosing a safe, evidence-backed treatment plan.

The Aesthetic Injectable Landscape: Regulatory & Mechanistic Comparison:
┌────────────────────────────────┬──────────────┬──────────────┬───────────────────────────────┐
│ Product                        │ Polymer / Bio│ U.S. Status  │ Primary Clinical Niche        │
├────────────────────────────────┼──────────────┼──────────────┼───────────────────────────────┤
│ **Juvelook**                   │ PDLLA + HA   │ Unapproved   │ Micro-depressions, texture    │
│ **Juvelook Volume (Lenisna)**  │ PDLLA + HA   │ Unapproved   │ Deep folds, facial volume     │
│ **Sculptra**                   │ PLLA         │ FDA PMA      │ Structural collagen, cheeks   │
│ **Skinvive by Juvéderm**       │ Micro-HA     │ FDA PMA      │ Intradermal cheek smoothness  │
│ **Rejuran Healer**             │ Polynucleotid│ Unapproved   │ Cellular repair, barrier      │
│ **Ellansé**                    │ PCL + CMC    │ Unapproved   │ Immediate volume + biostim    │
│ **Radiesse**                   │ CaHA + CMC   │ FDA PMA      │ Immediate lift + collagen     │
└────────────────────────────────┴──────────────┴──────────────┴───────────────────────────────┘

1. Juvelook vs. Sculptra (PLLA)

The comparison between Juvelook and Sculptra is the most frequent biostimulator head-to-head:

• Approval Standing: Sculptra holds PMA P030050, with extensive safety tracking in the U.S. since 2004. Its clinical dossier proves up to 24 months of sustained efficacy for nasolabial folds and cheek wrinkles. Juvelook holds zero U.S. approvals.
• Physical Structure: Sculptra's PLLA microparticles are irregular and crystalline. The FDA S039 overview says the product is reconstituted with sterile water before use. Juvelook's manufacturer describes spherical, porous PDLLA in a non-crosslinked HA carrier. That design difference is marketing and literature, not a borrowed Sculptra PMA.
• Target Plane: The FDA S039 overview says Sculptra is injected under the skin (subcutaneous) for cheek lines. Superficial intradermal placement of particulate PLLA is a known papule risk on labeled US use. Manufacturer Juvelook copy describes a skin-booster / texture role for the 50 mg SKU and a volume role for Volume/Lenisna; those are foreign commercial roles, not US labeled planes. For labeled US PLLA-versus-CaHA shopping, see Sculptra vs. Radiesse. For off-label body PLLA, see Sculptra for buttocks.

2. Juvelook vs. Skinvive by Juvéderm (Microdroplet HA)

For patients seeking the radiant "Korean glass skin" effect, the primary legal U.S. alternative to Juvelook is Skinvive by Juvéderm:

• Approval Standing: Skinvive holds PMA P110033/S059 (11 May 2023, cheek skin smoothness) and supplement S099 (11 June 2026, neck lines). It is the only FDA-approved intradermal microdroplet skin booster in the United States (detailed in FDA-approved skin boosters and Skinvive neck).
• Mechanism: Skinvive is crosslinked hyaluronic acid delivered as microdroplets. Its labeled job is skin smoothness via a hydrating HA gel, not a PDLLA foreign-body collagen cascade. Juvelook's long-term pitch is PDLLA microparticles; its HA is a non-crosslinked carrier on the manufacturer lineup.
• Reversibility: Skinvive is an HA gel, so hyaluronidase is the reversal tool for HA. That is not a guarantee of instant or complete reversal in every placement. Juvelook's PDLLA fraction is not hyaluronidase-reversible.

3. Juvelook vs. Rejuran (Polynucleotides / PN)

Both Juvelook and Rejuran Healer dominate the Korean aesthetic market, leading many consumers to conflate them:

• Mechanism: Rejuran is composed of polynucleotides (PN) extracted from wild salmon DNA. It is a biological wound-healing stimulator that promotes cellular regeneration, microcirculation, and anti-inflammatory signaling without acting as a physical particulate foreign body. Juvelook is a synthetic polymer (PDLLA) that induces structural neocollagenesis through controlled foreign-body encapsulation.
• U.S. Status: Neither product is FDA-approved as an injectable. Like Juvelook, Rejuran is marketed in the U.S. only as a topical cosmetic skincare serum, while its injectable formulations remain unapproved foreign devices (see our comparative analysis in Rejuran vs. Skinvive).

4. Juvelook vs. Ellansé (PCL)

As highlighted by the errors on California clinic websites, Juvelook and Ellansé are frequently mixed up:

• Polymer: Ellansé consists of polycaprolactone (PCL) microspheres in a carboxymethylcellulose (CMC) carrier. Juvelook consists of poly-D,L-lactic acid (PDLLA) in an uncrosslinked hyaluronic acid carrier.
• U.S. Status: Both products hold European CE marks and Asian authorizations in manufacturer or clinic copy, but neither is a US filler PMA. Sinclair's US Ellansé program is the unapproved-device trial NCT06984835 (see Ellansé FDA status). The Juvelook snapshot used here contains no matching PMA. A ClinicalTrials.gov record can discuss Juvelook as a CE-marked Korean product; that is not a US approval order.

---

Who should skip a Juvelook quote (FDA-approved-filler claim, undereye PMA, MoCRA serum swap, PCL mix-up)?

Given the regulatory restrictions, provenance hazards, and clinical risks surrounding Juvelook in the United States, prospective patients should decline or postpone a treatment quote if any of the following five red flags emerge during a consultation.

Juvelook Quote Red-Flag Audit:
┌───────────────────────────────────────────────────────────────────────────────────────────────┐
│ 1. The Practice Claims Juvelook is "FDA-Approved"                                            │
│    • Any quote asserting FDA approval, clearance, or listing as an injectable is false.      │
│    • Decline immediately; the practice is either misinformed or deceptively marketing.       │
├───────────────────────────────────────────────────────────────────────────────────────────────┤
│ 2. The Clinic Claims an FDA Indication for Undereye Hollows                                  │
│    • Repeating Jeunex-style claims of an "undereye FDA approval" is a critical safety failure.│
│    • PDLLA in the tear trough carries severe risks of persistent, non-dissolvable nodules.    │
├───────────────────────────────────────────────────────────────────────────────────────────────┤
│ 3. The Provider Uses VAIM USA's Topical MoCRA Serum for Injection                            │
│    • Drawing up a cosmetic serum labeled "Not intended for injection" violates federal law.  │
│    • Injects unsterilized cosmetic agents, exposing tissue to profound infection risks.       │
├───────────────────────────────────────────────────────────────────────────────────────────────┤
│ 4. The Practice Confuses the Polymer (Calling it PCL or Sculptra)                             │
│    • Clinics confusing PDLLA with Ellansé's PCL or Sculptra's PLLA lack basic fluency.       │
│    • An injector who does not understand the polymer cannot manage delayed complications.     │
├───────────────────────────────────────────────────────────────────────────────────────────────┤
│ 5. The Patient Demands Complete Reversibility                                                │
│    • Hyaluronidase hydrolyzes ONLY the minor HA carrier; it CANNOT dissolve PDLLA particles. │
│    • Patients who cannot accept an irreversible particulate implant should choose HA fillers.  │
└───────────────────────────────────────────────────────────────────────────────────────────────┘

1. The Provider Claims the Injectable is "FDA-Approved"

If a medical spa, dermatologist, or plastic surgeon tells you that injectable Juvelook or Lenisna is "FDA-approved," "FDA-cleared," or "cleared under a foreign equivalence fast-track," decline the quote immediately.

There is no foreign equivalence fast-track for Class III medical devices. When a practice misrepresents an unapproved, gray-market product as FDA-approved, they demonstrate either a profound ignorance of medical device law or a willingness to mislead patients to capture procedural revenue. In either scenario, patient safety is compromised.

2. The Clinic Proposes Juvelook for the Tear Troughs or Undereye Area

If an injector recommends Juvelook or Juvelook Volume to treat dark circles, under-eye bags, or tear-trough hollows, exercise extreme caution.

Particulate biostimulators can leave delayed, visible nodules in thin lower-eyelid skin. Unlike hyaluronic acid, which can be dissolved with hyaluronidase (see dissolving filler with hyaluronidase), PDLLA microparticles cannot be dissolved. Nodule management is then a clinician decision; this page does not publish a treatment protocol.

If you require tear-trough correction, ask for an FDA-approved on-label hyaluronic acid filler — currently Volbella XC, Restylane Eyelight, Belotero Balance (+), or RHA Redensity Eye — not a particulate biostimulator with no US PMA.

3. The Practice Injects the Topical MoCRA Serum

Ask to see the packaging of the product before it is prepared. If the vial or box displays "JUVELOOK Professional Skincare", an Irvine, California address, or FDA MoCRA #53-670426-700897, inspect the fine print.

If the label states "Not intended for injection", do not allow the provider to draw it into a syringe or inject it into your skin. Utilizing a topically registered cosmetic formulation as an intradermal or subdermal injectable contradicts the manufacturer's own "not intended for injection" line and bypasses Class III device controls. If a practice offers microneedling with topical Juvelook as a surface glide, that is a different, cosmetic use — provided the serum is not injected beneath the skin.

4. The Clinic Confuses the Underlying Polymer

If the clinic’s promotional materials or staff describe Juvelook as containing "PCL microspheres" (confusing it with Ellansé) or tell you that it is "the exact same thing as Sculptra," they do not understand the biomaterial they are implanting into your face. Different polymers exhibit distinct degradation profiles, foreign-body responses, and complication management pathways. An aesthetic clinician who does not understand the molecular distinction between PCL, PLLA, and PDLLA cannot be trusted to manage an adverse event or vascular emergency.

5. You Require an Instantly Reversible Treatment

One of the greatest safety nets in modern aesthetic medicine is the availability of hyaluronidase to dissolve hyaluronic acid fillers in the event of an aesthetic misplacement, overfilling, or an acute vascular occlusion (analyzed in our clinical protocol on filler vascular occlusion).

While Juvelook contains hyaluronic acid, the HA serves merely as a temporary lubricating vehicle (7.5 mg in standard Juvelook; 30 mg in Volume). The overwhelming majority of the product's dry weight consists of insoluble poly-D,L-lactic acid microparticles (42.5 mg and 170 mg, respectively).

• If an injector accidentally enters a facial vessel (such as the facial, angular, or supratrochlear artery) with Juvelook, injecting hyaluronidase will dissolve the HA carrier, but it will leave the PDLLA microparticles mechanically lodged within the arterial lumen.
• If a patient experiences a visible contour irregularity or delayed granuloma, hyaluronidase cannot remove the collagen-stimulating polymer.

Patients who are anxious about semi-permanent changes, or who are new to facial injectables, should treat non-dissolvable particles as a hard skip unless they accept that hyaluronidase will not rescue the polymer. For a broader comparison of labeled collagen stimulators versus HA, see biostimulators vs. HA fillers.

What does injectable Juvelook cost in the United States?

There is no US PMA list price for injectable Juvelook because there is no US PMA. Manufacturer and medical-tourism pages quote foreign clinic fees as commercial copy, not a labeled US fee schedule. A US quote for "Juvelook" should be asked against the SKU on the tray: the Irvine topical serum is a cosmetic product; an imported vial is not a priced, approved device.

---

Frequently Asked Questions

Is Juvelook FDA-approved in the United States?

No. Juvelook is not an FDA-approved dermal filler or skin booster in the United States. In a 24 August 2026 snapshot of the FDA PMA database (56,765 rows; 1,046 LMH records; latest decision date 10 July 2026), Juvelook, Lenisna, and VAIM hold zero Premarket Approvals. The matching 510(k) snapshot (175,559 rows) has zero matching product or applicant rows. The official FDA-Approved Dermal Fillers materials list names hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid (PLLA), and PMMA; poly-D,L-lactic acid (PDLLA) is absent.

Can you get Juvelook in the US?

You can legally obtain JUVELOOK Professional Skincare, distributed by VAIM USA (Irvine, CA) as a topical cosmetic serum registered under FDA MoCRA (#53-670426-700897) and labeled not intended for injection. Injectable Juvelook is not an FDA-approved US commercial device. Ranking US clinic pages describe injection; this page cannot verify how those practices source vials. Ask which SKU is on the tray.

Is Juvelook the same as Sculptra?

No. While both are lactic-acid biostimulators, Sculptra is poly-L-lactic acid (PLLA) and holds FDA Premarket Approval (PMA P030050), with S039 language that results may last up to 24 months (see how long Sculptra takes to work). Juvelook is amorphous poly-D,L-lactic acid (PDLLA) plus non-crosslinked HA. Clinic and manufacturer pages quote commercial duration windows; those are not a US label. Juvelook holds zero US FDA approvals.

Is Lenisna or Juvelook Volume FDA-approved?

No. Lenisna (the international brand name for Juvelook Volume) is identical in formulation (170 mg PDLLA + 30 mg HA) and holds zero U.S. FDA PMAs or clearances. Claims by international clinics that Juvelook Volume holds an FDA approval—specifically for undereye hollows—are completely false. Lenisna is approved as a medical device in South Korea (MFDS) and holds a European CE mark, but has no U.S. approval.

Is the Juvelook product sold in the US the injectable or a topical serum?

The authorized commercial product marketed in the United States by VAIM USA is strictly a topical skincare serum. It is designed to be applied onto the surface of the skin following cosmetic procedures like microneedling. It is not an injectable device, and its product packaging explicitly states that it is not intended for injection.

Can Juvelook be dissolved with hyaluronidase?

No. Hyaluronidase hydrolyzes hyaluronic acid. While hyaluronidase can break down the small hyaluronic acid carrier in Juvelook (7.5 mg in standard Juvelook, 30 mg in Lenisna), it has zero enzymatic effect on the insoluble poly-D,L-lactic acid (PDLLA) microparticles, which constitute the vast majority of the formulation. Any nodule, granuloma, or contour irregularity caused by the PDLLA polymer cannot be dissolved with hyaluronidase.

---

What to Ask If a Clinic Quotes Juvelook

If you consult with an aesthetic medical practice in the United States and the clinician recommends or quotes a Juvelook treatment, protect your health, safety, and legal rights by asking these five direct questions:

1. "Can you confirm that Juvelook does NOT hold an FDA Premarket Approval (PMA) as a dermal filler or skin booster in the United States?"
   Why to ask: Establishes whether the injector is honest and transparent about the product's regulatory standing, or whether they are repeating commercial marketing lines that falsely claim FDA approval.
2. "Are you injecting an imported foreign medical device, or are you injecting VAIM USA’s topical MoCRA-registered cosmetic serum?"
   Why to ask: Protects you from having a topical cosmetic serum injected into your vascular tissues, and clarifies the exact provenance and chain-of-custody of the vial being used.
3. "Why are you recommending an unapproved foreign PDLLA injectable over FDA-approved alternatives like Skinvive (PMA P110033) for skin quality or Sculptra (PMA P030050) for collagen stimulation?"
   Why to ask: Forces the injector to provide a clinical rationale for bypassing FDA-approved Class III devices that carry proven safety dossiers and public SSED trial data.
4. "What is your exact protocol if an adverse event, delayed nodule, or vascular occlusion occurs, given that PDLLA microparticles CANNOT be dissolved with hyaluronidase?"
   Why to ask: Ensures the provider understands that the product is non-dissolvable, and verifies they have an emergency clinical protocol for particulate vascular compromise that does not rely on hyaluronidase alone.
5. "If you are treating the under-eye or tear-trough area, why are you using a particulate biostimulator rather than an FDA-approved, on-label hyaluronic acid filler (Volbella XC, Restylane Eyelight, Belotero Balance (+), or RHA Redensity Eye)?"
   Why to ask: Shields you from devastating periorbital nodule complications and directly challenges the fabricated "undereye FDA approval" claims circulating on search engines.

For broader clinical guidance on aesthetic device clearances, off-label consent standards, and biologic safety, explore our reference guides to FDA-approved skin boosters, Korean aesthetic devices in the US market, off-label aesthetic injections, hybrid biostimulators like HArmonyCa, and unapproved regenerative aesthetic treatments.

---

Sources

• FDA Center for Devices and Radiological Health, FDA-Approved Dermal Fillers (Lists approved material classes: HA, CaHA, PLLA, PMMA; page dateModified November 9, 2020): https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/fda-approved-dermal-fillers
• FDA Center for Devices and Radiological Health, Dermal Fillers (Soft Tissue Fillers) Information and Safety Warnings (Content current as of July 6, 2023): https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/dermal-fillers-soft-tissue-fillers
• FDA CDRH Premarket Approval (PMA) Database (product code LMH; this page's census: 1,046 LMH rows in a 24 August 2026 snapshot, latest decision date 10 July 2026): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm
• FDA CDRH Premarket Approval Database, PMA P030050 (Sculptra Injectable Poly-L-lactic Acid; Original Approval August 3, 2004; Applicant: Q-Med AB / Galderma): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P030050
• FDA CDRH, Sculptra P030050/S039 Approval Summary (Cheek wrinkles supplement approval, April 25, 2023): https://www.fda.gov/medical-devices/recently-approved-devices/sculptra-p030050s039
• FDA CDRH Premarket Approval Database, PMA P110033/S059 (Skinvive by Juvéderm; decision 11 May 2023, cheek smoothness; applicant Allergan): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110033S059
• FDA CDRH Premarket Approval Database, PMA P110033/S099 (Skinvive neck-lines indication; decision 11 June 2026): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110033S099
• FDA CDRH Premarket Approval Database, PMA P110033/S053 (Juvéderm Volbella XC infraorbital hollows; 28 May 2021): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110033S053
• FDA CDRH Premarket Approval Database, PMA P040024/S135 (Restylane Eyelight infraorbital hollows; 8 May 2023): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P040024S135
• FDA CDRH Premarket Approval Database, PMA P090016/S050 (Belotero Balance (+) infraorbital hollows; 27 September 2023): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P090016S050
• FDA CDRH Premarket Approval Database, PMA P170002/S050 (RHA Redensity Eye infraorbital hollows; 12 May 2026): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170002S050
• FDA CDRH 510(k) Premarket Notification Database (this page's census: 175,559 rows in a 24 August 2026 snapshot): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
• FDA Center for Food Safety and Applied Nutrition, Modernization of Cosmetics Regulation Act of 2022 (MoCRA) (Facility registration and cosmetic product listing overview): https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra
• VAIM Global / VAIM Co., Ltd., JUVELOOK Frequently Asked Questions (Manufacturer regulatory statement: CE-marked Class III medical device, MFDS approved; export only; indications vary by country; retrieved September 8, 2026): https://juvelook.com/en/company/faq.php
• VAIM Global, JUVELOOK Product Specifications and Lineup (Juvelook 42.5/7.5 mg; Juvelook Volume 170/30 mg; Juvelook i; Juvelook Glam; retrieved September 8, 2026): https://juvelook.com/
• VAIM Global, JUVELOOK Registrations and Benefits (Lists CE, KFDA, and TGA registrations; retrieved September 8, 2026): https://juvelook.com/en/company/benefits.php
• VAIM USA, JUVELOOK Professional Skincare (Topical cosmetic post-procedure serum; FDA MoCRA #53-670426-700897; labeled "Not intended for injection"; Irvine, CA; retrieved September 8, 2026): https://www.usa.juvelook.com/
• Jeunex Clinic, Juvelook Volume for dark undereye circles (Incumbent SERP error: claims FDA and KFDA approval specifically for undereye hollows; retrieved September 8, 2026): https://eng.jeunexclinic.com/juvelook-volume-for-dark-undereye-circles/
• Edition Clinic Bangkok, Is Juvelook a Filler? Here's What It Actually Is (Incumbent SERP error: claims US FDA approval because ingredients are biodegradable; retrieved September 8, 2026): https://editionbkk.com/blog/is-juvelook-a-filler/
• Girin Plastic Surgery, Juvelook & Juvelook Volume in Korea (Incumbent SERP error: claims approval from both U.S. FDA and Korean FDA; retrieved September 8, 2026): https://www.girinpsen.com/juvelook
• Halo Beverly Hills, JuveLook Service Overview (US clinic marketing injectable JuveLook; incorrectly describes polymer as PCL microspheres; retrieved September 8, 2026): https://www.halobeverlyhills.com/services/juvelook/
• Halo Beverly Hills, Juvelook Volume Service Overview (US clinic marketing injectable Juvelook Volume as a dermal filler; retrieved September 8, 2026): https://www.halobeverlyhills.com/services/juvelook-volume/
• Cara Plastic Surgery Los Angeles, Juvelook Injectable Biostimulator (US clinic marketing Juvelook as an injectable; retrieved September 8, 2026): https://www.caraplasticsurgery.com/los-angeles/injectables/juvelook/
• Dr. Roy Kim, Comparing Skin Booster Treatments in the USA and Korea (Honest clinical incumbent: states Juvelook is not available in the USA and has no FDA approval; retrieved September 8, 2026): https://www.drkim.com/blogs/comparing-skin-booster-treatments-in-the-usa-and-korea
• Jane Yoo MD, Lenisna (states CE and KFDA approval; retrieved September 8, 2026): https://www.janeyoomd.com/k-beauty/lenisna/
• Seo SB, Park H, Jo JY, Ryu HJ. Skin rejuvenation effect of the combined PDLLA and non cross-linked hyaluronic acid: a preliminary study. J Cosmet Dermatol. 2024;23(3):794-802. doi:10.1111/jocd.16085. PMID 37969055 (VAIM Co., Ltd. funding disclosed on PubMed): https://pubmed.ncbi.nlm.nih.gov/37969055/
• Lee KWA, Chan LKW, Lee AWK, Lee CH, Wong STH, Yi KH. Poly-d,l-lactic Acid (PDLLA) Application in Dermatology: A Literature Review. Polymers (Basel). 2024;16(18):2583. doi:10.3390/polym16182583. PMID 39339047; PMC11434839: https://pmc.ncbi.nlm.nih.gov/articles/PMC11434839/
• Seo SB, Wan J, Yi KH. Energy-based device management of nodular reaction following poly-D,L-lactic acid injection for tear trough rejuvenation. J Cosmet Dermatol. 2025;24(1):e16575. PMID 39283001 (literature on a periorbital PDLLA nodule, not a PMA or a treatment protocol): https://pubmed.ncbi.nlm.nih.gov/39283001/